<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Vaccines (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Vaccines (Basel)</journal-id><journal-id journal-id-type="publisher-id">vaccines</journal-id><journal-title-group><journal-title>Vaccines</journal-title></journal-title-group><issn pub-type="epub">2076-393X</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40006728</article-id><article-id pub-id-type="pmc">PMC11860428</article-id><article-id pub-id-type="doi">10.3390/vaccines13020181</article-id><article-id pub-id-type="publisher-id">vaccines-13-00181</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Plasma microRNAs to Select Optimal Patients for Antibody Production from Anti-Addiction Vaccines</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kosten</surname><given-names>Thomas R.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing &#x02013; original draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding acquisition/">Funding acquisition</role><xref rid="af1-vaccines-13-00181" ref-type="aff">1</xref><xref rid="c1-vaccines-13-00181" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Koirala</surname><given-names>Amrit</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><xref rid="af2-vaccines-13-00181" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Nielsen</surname><given-names>David A.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing &#x02013; review &#x00026; editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af3-vaccines-13-00181" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Domingo</surname><given-names>Coreen B.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project administration/">Project administration</role><xref rid="af3-vaccines-13-00181" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-3120-6397</contrib-id><name><surname>Thomas</surname><given-names>Ynhi T.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing &#x02013; review &#x00026; editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af4-vaccines-13-00181" ref-type="aff">4</xref><xref rid="af5-vaccines-13-00181" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name><surname>Gunaratne</surname><given-names>Preethi H.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing &#x02013; review &#x00026; editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af6-vaccines-13-00181" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name><surname>Coarfa</surname><given-names>Cristian</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing &#x02013; review &#x00026; editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af7-vaccines-13-00181" ref-type="aff">7</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Casuccio</surname><given-names>Alessandra</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-vaccines-13-00181"><label>1</label>Department of Psychiatry and Behavioral Sciences, Department of Pharmacology, Department of Neuroscience, Department of Immunology, Baylor College of Medicine, Houston, TX 77030, USA</aff><aff id="af2-vaccines-13-00181"><label>2</label>Center for Precision Environmental Health, Baylor College of Medicine, Houston, TX 77030, USA; <email>amrit.koirala@bcm.edu</email></aff><aff id="af3-vaccines-13-00181"><label>3</label>Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, TX 77030, USA; <email>isailfast@gmail.com</email> (D.A.N.); <email>cdomingo@bcm.edu</email> (C.B.D.)</aff><aff id="af4-vaccines-13-00181"><label>4</label>Henry J.N. Taub Hospital Department of Emergency Medicine, Baylor College of Medicine, Houston, TX 77030, USA; <email>ynhi.thomas@bcm.edu</email></aff><aff id="af5-vaccines-13-00181"><label>5</label>Michael E. DeBakey VA Medical Center, Center for Innovations in Quality, Effectiveness, and Safety, Houston, TX 77030, USA</aff><aff id="af6-vaccines-13-00181"><label>6</label>Department of Biology and Biochemistry, University of Houston, Houston, TX 77204, USA; <email>phgunara@central.uh.edu</email></aff><aff id="af7-vaccines-13-00181"><label>7</label>Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA; <email>coarfa@bcm.edu</email></aff><author-notes><corresp id="c1-vaccines-13-00181"><label>*</label>Correspondence: <email>kosten@bcm.edu</email>; Tel.: +713-798-8628</corresp></author-notes><pub-date pub-type="epub"><day>13</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>13</volume><issue>2</issue><elocation-id>181</elocation-id><history><date date-type="received"><day>16</day><month>12</month><year>2024</year></date><date date-type="rev-recd"><day>03</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>07</day><month>2</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p><bold>Background</bold>: Cocaine and illicit amphetamines (disguised as &#x0201c;Adderall&#x0201d;) are being laced with fentanyl and producing accidental and intentional fatal overdoses. Vaccines can prevent these overdoses, but 33% of humans generate insufficient anti-drug antibody (AB) levels. Plasma microRNAs (miRs) can be used to predict non-responders. We have plasma stored from 152 cocaine vaccine trial participants following three vaccinations over 9 weeks and examined miRs as potential response biomarkers. <bold>Methods</bold>: We compared 2517 miRs before anti-cocaine vaccination in participants with the highest (n = 25) to the lowest (n = 23) antibody levels. False Discovery Rates (FDRs) were applied to identify differentially expressed (DE) miRs. We used miR target prediction pipelines to identify the miR-regulated genes. <bold>Results</bold>: Using a DE-FDR &#x0003c; 0.05 and a &#x0003e;3-fold difference between high- and low-AB responders yielded 12 miRs down and 3 miRs up compared to low-AB patients. Furthermore, 11 among 1673 genes were targeted by 3 or more of the 12 down DE-miRs. <bold>Conclusions</bold>: A significant DE-miR for identifying optimal antibody responders replicated previous vaccine study predictors (miR-150), and several more miRs appear to be strong candidates for future consideration in replications based upon significance of individual DE-miRs and upon multiple miRs converging on individual genes.</p></abstract><kwd-group><kwd>human vaccine</kwd><kwd>cocaine</kwd><kwd>microRNA</kwd><kwd>antibody response</kwd><kwd>epigenetics</kwd><kwd>drug overdose</kwd><kwd>biomarker</kwd></kwd-group><funding-group><award-group><funding-source>USA NIH, National Institute on Drug Abuse (NIDA)</funding-source><award-id>R01-DA025223</award-id></award-group><award-group><funding-source>John O&#x02019;Quinn Foundation</funding-source></award-group><award-group><funding-source>Waggoner Chair Endowment</funding-source></award-group><award-group><funding-source>Toomim Foundation</funding-source></award-group><funding-statement>This research was funded by USA NIH, National Institute on Drug Abuse (NIDA) grant number R01-DA025223 for original data collection, and by the John O&#x02019;Quinn Foundation, the Waggoner Chair Endowment, and the Toomim Foundation for the secondary microRNA data analyses.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-vaccines-13-00181"><title>1. Introduction</title><p>The fentanyl overdose epidemic has significantly increased fatalities from both opioid and, more recently, stimulant overdoses [<xref rid="B1-vaccines-13-00181" ref-type="bibr">1</xref>]. Fentanyl is highly lethal because it powerfully suppresses respiration, leading to potential respiratory failure and death [<xref rid="B2-vaccines-13-00181" ref-type="bibr">2</xref>]. Its spread into stimulant overdoses involving cocaine and methamphetamines is largely due to the ease with which low-quality batches of these drugs can be adulterated with fentanyl. For drug dealers, fentanyl is appealing due to its low cost and relative simplicity of its manufacture and transport from sources in Mexico and China. Even small fentanyl quantities can yield millions of dollars in sales, particularly with the rising adulteration of illicit stimulants.</p><p>The therapeutic challenge arises because the adulteration of cocaine and illicit &#x0201c;Adderall&#x0201d; with fentanyl has incorporated these stimulants into the fentanyl overdose epidemic. This underscores the urgent need for effective therapeutics, particularly blockers, for all three drugs. However, no FDA-approved pharmacotherapies specifically target cocaine, which affects over 5 million abusers; amphetamine, with 3 million abusers; or fentanyl, with 1 million &#x0201c;direct&#x0201d; abusers [<xref rid="B3-vaccines-13-00181" ref-type="bibr">3</xref>]. The search for therapeutics, particularly blockers, has highlighted the potential of vaccines that produce sustained antibodies (ABs) to neutralize these substances [<xref rid="B4-vaccines-13-00181" ref-type="bibr">4</xref>]. Despite extensive research over the past 30 years, anti-drug vaccine trials have found that only two-thirds of patients achieve sufficient AB levels to block the targeted drugs. This emphasizes the critical need for biomarkers to not only identify patients likely to respond well, but also to recognize those who may need alternative vaccine formulations to produce the necessary high AB levels.</p><p>A completed clinical trial of an anti-cocaine vaccine involving 152 vaccinated patients with stored plasma offers an opportunity to discover biomarkers. Plasma microRNAs (miRs), which have been associated with high-AB responses to various vaccines [<xref rid="B5-vaccines-13-00181" ref-type="bibr">5</xref>], are promising candidates. Therefore, we designed this post hoc study to replicate these miR studies by comparing the highest- to lowest-antibody responders from the completed cocaine vaccine trial.</p><p>The efficacy of vaccines for producing optimal AB levels and affinities varies among individuals and is often enhanced by the inclusion of adjuvants [<xref rid="B6-vaccines-13-00181" ref-type="bibr">6</xref>]. The vaccine&#x02019;s antigen is often a bacterial protein or inactivated virus, as seen in recent anti-COVID-19 vaccines. For smaller molecular targets, known as haptens, vaccines are developed by attaching the hapten to a larger immunogenic protein, such as tetanus toxoid or a subunit of cholera B toxoid [<xref rid="B7-vaccines-13-00181" ref-type="bibr">7</xref>]. This haptenated vaccine approach has been used to develop vaccines against various substances of abuse, including opioids (e.g., fentanyl), stimulants (e.g., cocaine, methamphetamine), and nicotine [<xref rid="B7-vaccines-13-00181" ref-type="bibr">7</xref>,<xref rid="B8-vaccines-13-00181" ref-type="bibr">8</xref>]. A common adjuvant used in these vaccines is an aluminum salt, which induces pro-inflammatory cytokine expression and the activation of dendritic cells and macrophages. These cells lead to the priming of na&#x000ef;ve T cells and provoke antigen-specific immune responses, including B cell activation and AB production [<xref rid="B6-vaccines-13-00181" ref-type="bibr">6</xref>].</p><p>Chronic inflammation can impair vaccine efficacy through several mechanisms, including the excessive TNF-alpha suppression of T and B cells [<xref rid="B9-vaccines-13-00181" ref-type="bibr">9</xref>,<xref rid="B10-vaccines-13-00181" ref-type="bibr">10</xref>]. Substance use disorder patients develop chronic inflammation from excessive release of neurotransmitters due to the drugs binding to receptors expressed on glial cells and amplifying inflammatory signaling via release of cytokines and chemokines, potentially contributing to the positive feedback that promotes inflammation [<xref rid="B11-vaccines-13-00181" ref-type="bibr">11</xref>]. The suppression of this chronic inflammation can improve vaccine responses. Innate immune responses are critical to the humoral response for vaccine efficacy, and several miRs regulate and enhance these responses through cytokines suppressing pro-inflammatory expression [<xref rid="B5-vaccines-13-00181" ref-type="bibr">5</xref>,<xref rid="B12-vaccines-13-00181" ref-type="bibr">12</xref>,<xref rid="B13-vaccines-13-00181" ref-type="bibr">13</xref>,<xref rid="B14-vaccines-13-00181" ref-type="bibr">14</xref>,<xref rid="B15-vaccines-13-00181" ref-type="bibr">15</xref>,<xref rid="B16-vaccines-13-00181" ref-type="bibr">16</xref>,,<xref rid="B17-vaccines-13-00181" ref-type="bibr">17</xref>,<xref rid="B18-vaccines-13-00181" ref-type="bibr">18</xref>,<xref rid="B19-vaccines-13-00181" ref-type="bibr">19</xref>]. Thus, miRs are pivotal in regulating vaccine responses and may be particularly important for individuals with active substance use disorders, as chronic inflammation can hinder their AB responses to haptenated vaccines.</p><p>Importantly, while treatments to inhibit this response through specific miRs are a future possibility, miRs can more immediately serve as biomarkers for identifying poor or enhanced responders to anti-addiction vaccines, paralleling their emerging roles in cancer, diabetes, Alzheimer&#x02032;s disease, allergic inflammatory disease, rheumatoid arthritis, and other chronic inflammatory and degenerative diseases [<xref rid="B20-vaccines-13-00181" ref-type="bibr">20</xref>]. Several studies have recognized the importance of identifying pre-vaccination miR associated with strong AB responses among infectious diseases such as influenza, Ebola, and COVID-19 [<xref rid="B5-vaccines-13-00181" ref-type="bibr">5</xref>,<xref rid="B21-vaccines-13-00181" ref-type="bibr">21</xref>,<xref rid="B22-vaccines-13-00181" ref-type="bibr">22</xref>]. Both whole blood and exosomal miRs were primarily positively correlated with AB levels obtained from 14 to 360 days after vaccination in a small sample of subjects given Ebola vaccination. For Ebola, these included miR-5196, 508, 3179, 5685, 155, and 382 and somewhat different and more diverse miRs for exosomes including 486, 410, 98, 4475, 4763, 1271, 6750, 1973, 3156, 487a, 369, 200a, 372, and 584n [<xref rid="B22-vaccines-13-00181" ref-type="bibr">22</xref>]. MiR-486, 410, and 98 were particularly interesting for the Ebola study because of their regulation of cytokine response via the NF-kB pathway and IL-6 signaling [<xref rid="B23-vaccines-13-00181" ref-type="bibr">23</xref>,<xref rid="B24-vaccines-13-00181" ref-type="bibr">24</xref>]. The influenza vaccine work in 53 older subjects found a more consolidated group of three, miR-150, 629, and 4443, that were correlated with immune outcomes across several cell types particularly in CD4+ T cells [<xref rid="B21-vaccines-13-00181" ref-type="bibr">21</xref>]. Important signaling pathways included TGF-beta, PI3K-Akt, p53, MAPK, TNF, and C-type lectin receptor signaling. Earlier influenza vaccine studies found miR-451 and miR-192 to be important for AB responses, but these were not important for COVID vaccination [<xref rid="B25-vaccines-13-00181" ref-type="bibr">25</xref>]. The COVID vaccine study using Pfizer BNT162b2 in 61 subjects focused on sixteen exosomal miRs in blood and identified two of interest, miR92a-2-5p and 148a, and three others with weaker associations with AB levels: miR-132, 221, and 625-3p [<xref rid="B5-vaccines-13-00181" ref-type="bibr">5</xref>]. Thus, the aim of this post hoc study is to replicate previous findings on miR biomarkers for predicting strong AB responses with anti-addiction vaccines. This study compares two subgroups in the completed cocaine vaccine clinical trial: the highest- and lowest-AB responders.</p></sec><sec id="sec2-vaccines-13-00181"><title>2. Materials and Methods</title><sec sec-type="methods" id="sec2dot1-vaccines-13-00181"><title>2.1. Subjects and Vaccination Procedures</title><p>Our team enrolled 300 patients into a randomized, placebo-controlled clinical trial of the anti-cocaine vaccine, TA-CD, from 2010 to 2012 (ClinicalTrials.gov, NCT00969878). The TA-CD vaccine consists of succinyl norcocaine covalently linked to cholera toxin B (SNC-rCTB), adsorbed onto an aluminum hydroxide adjuvant. Subjects were randomized to five 0.5 mL intramuscular vaccinations of 400 micrograms of active (SNC-rCTB) vaccine at weeks 1, 3, 5, 9, and 13 [<xref rid="B26-vaccines-13-00181" ref-type="bibr">26</xref>]. Due to a higher completion rate among the high-AB-response group compared to the low group (93% vs. 80%), we focused our post hoc analysis on participants who completed at least 3 injections and had AB levels assessed at week 9, which was 4 weeks after the second booster. We selected stored frozen plasma from 48 participants for comparison, comprising 25 with the highest IgG AB responses and 23 with the lowest responses among the 152 actively vaccinated participants [<xref rid="B27-vaccines-13-00181" ref-type="bibr">27</xref>].</p><p>Blood samples were collected prior to the first vaccination, and no participants had urine samples indicating recent cocaine use. All participants met DSM-IV criteria for current cocaine use disorder, having provided a benzoylecgonine-positive urine sample within two weeks prior to blood sampling and study randomization. As expected, mean IgG AB levels at week 9 significantly differed between the two groups (16.7 vs. 132.0 mcg/mL; <italic toggle="yes">p</italic> &#x0003c; 0.01). As previously published, the cholera B toxoid-based vaccine produced significant IgG AB levels against this carrier protein in all patients, supporting the specificity of variations in the anti-cocaine AB as independent of the response to the cholera carrier [<xref rid="B26-vaccines-13-00181" ref-type="bibr">26</xref>,<xref rid="B27-vaccines-13-00181" ref-type="bibr">27</xref>]. Interestingly, IgM and IgA AB levels were not correlated with IgG AB responses, and pre-vaccination IgM levels against cocaine predicted poor anti-cocaine IgG levels after vaccination [<xref rid="B27-vaccines-13-00181" ref-type="bibr">27</xref>,<xref rid="B28-vaccines-13-00181" ref-type="bibr">28</xref>].</p><p>Baseline drug and alcohol use over the past month for these patients included a mean of 14 days (range: 7&#x02013;22) for cocaine, 0 days (0&#x02013;2) for cannabis, 4 days (1&#x02013;15) for alcohol, and 0 days (0&#x02013;4) for alcohol intoxication. Lifetime cocaine use averaged 16 years (range: 10&#x02013;22). The two groups did not differ in any of these drug use characteristics. Additionally, the demographics of the AB response groups were similar, with 19 out of 25 versus 17 out of 23 males, 15 out of 25 versus 15 out of 23 whites, and mean ages of 45.5 versus 44.3 years for the highest- and lowest-AB response groups, respectively.</p></sec><sec sec-type="methods" id="sec2dot2-vaccines-13-00181"><title>2.2. Epigenetic microRNA Procedures</title><p>The RNA was extracted from 250 &#x003bc;L serum samples using the miRNeasy Serum/Plasma Kit (Qiagen Cat: 217184). miRNA libraries were then prepared with the QIAseq miRNA Library Kit (Qiagen, Germantown, ML, USA, Cat: 331505). The prepared libraries were pooled at 2 nm and sequenced at the University of Houston UH-Seq Core using an Illumina NextSeq 2000, generating 10 million 76bp reads per sample. We processed the miR-Seq data using the ENCODE pipeline, performing mapping with STAR [<xref rid="B29-vaccines-13-00181" ref-type="bibr">29</xref>] and miRNA quantification using the miRBase reference [<xref rid="B30-vaccines-13-00181" ref-type="bibr">30</xref>]. In addition to whole blood plasma miR, we also extracted exosomes from the blood and sequenced those miRs separately for a parallel analysis. Finally, we and others have performed repeated miR sequencing on samples stored at &#x02212;80 &#x000b0;C for months and years and found that the batch effect changes across these time intervals were minimal [<xref rid="B31-vaccines-13-00181" ref-type="bibr">31</xref>].</p></sec><sec id="sec2dot3-vaccines-13-00181"><title>2.3. Statistical Analyses</title><p>Plasma DE miRs were compared between the high- and low-AB groups by analyzing the differential expression of each miR and adjusting significance levels for multiple comparisons using an FDR control. These two-way comparisons were displayed using volcano plots separating up-regulated from down-regulated DE miRs at the significance threshold of 2-fold DE and FDR adjusted <italic toggle="yes">p</italic>-value &#x0003c; 0.05. We also conducted sensitivity analyses by adjusting the FDR to &#x0003c;0.001 and considering DE miRs with 4- to 16-fold differences, allowing us to assess how the number of significant DE miRs were affected by these more stringent thresholds. The low versus high classification of patients before vaccination were compared for accuracy of that classification using a Random Forest technique. Cross-validation used 100 iterations, with samples split into 70% training and 30% testing sets. Since we expected to find about 50 DE miRs, we anticipated many gene targets, which we determined using miRDB [<xref rid="B32-vaccines-13-00181" ref-type="bibr">32</xref>].</p><p>We then reduced the number of essential miRs for identifying participants with optimal vaccine AB responses by increasing the FDR significance from <italic toggle="yes">p</italic> &#x0003c; 0.05 to <italic toggle="yes">p</italic> &#x0003c; 0.001 for the mean differences in individual miRs and by finding multiple miRs that converged on individual genes. In the volcano plot, the fold change is expressed as log<sub>2</sub> (e.g., 1 = 2-fold; 2 = 4-fold; 3 = 8-fold) and the significance levels (<italic toggle="yes">p</italic> &#x0003c; 0.00) for FDR values are expressed as &#x02212;log<sub>10</sub> (e.g., 1.3 = 0.05, 2 = 0.01, 3 = 0.001).</p></sec></sec><sec sec-type="results" id="sec3-vaccines-13-00181"><title>3. Results</title><p><xref rid="vaccines-13-00181-f001" ref-type="fig">Figure 1</xref> is a volcano plot showing the 2517 differentially expressed (DE) plasma miRs included in the comparison between the high- and low-AB-level responders. For the low- compared to high-AB responders, the right upper corner shows the up-regulated DE-miRs, while the upper left corner shows the down-regulated DE-miRs. Using a DE-FDR &#x0003c; 0.05 and a &#x0003e;3-fold difference between responders yielded 12 miRs that were down-regulated and 3 miRs that were up-regulated compared to low-AB patients. These 15 miRs are labeled in <xref rid="vaccines-13-00181-f001" ref-type="fig">Figure 1</xref>. The three up-regulated miRNAs were miR-3131, -519b, and -6748. The 12 down-regulated miRNAs were miR-3202, -150, -5481, -4800, -616, -6756, -1246, -4659, -3143, -556, -4747, and -5192. <xref rid="vaccines-13-00181-f002" ref-type="fig">Figure 2</xref> provides a heatmap showing the contrasting up- or down-regulation for each of the DE-miR for the high- versus low-AB responders. A similar analysis using the exosomal miR yielded 12 DE-miRs that differed &#x0003e; 3-fold at an FDR &#x0003c; 0.05. The exosomal miRs were miR-106b, 140, 142, 146a, 1273g, 32, 320c, 423, 4516, 4532, 6087, and 663.</p><p>The 3 up-regulated miRs targeted 382 unique genes, while the 12 down-regulated miRs targeted 1673 genes. None of the three up-regulated miR genes targeted overlapping genes, while three or more of the twelve down-regulated miRs targeted 11 genes as shown in <xref rid="vaccines-13-00181-f003" ref-type="fig">Figure 3</xref>. <xref rid="vaccines-13-00181-f003" ref-type="fig">Figure 3</xref> also shows three down-regulated miRs targeting four to seven different genes: miR-3202, -5481, and -3243. The potential relevance of these 12 down-regulated miRs to immune function was also highlighted by a tissue-type enrichment analysis of the targeted genes showing that gastric immune cell genes showed the strongest association of all the tissues analyzed (<italic toggle="yes">p</italic> &#x0003c; 10<sup>&#x02212;8</sup>) [<xref rid="B33-vaccines-13-00181" ref-type="bibr">33</xref>].</p></sec><sec sec-type="discussion" id="sec4-vaccines-13-00181"><title>4. Discussion</title><p>Comparing patients with high versus low IgG AB levels induced by a cholera-based anti-cocaine vaccine, we found that 15 out of 2517 plasma whole blood miRs distinguished these two groups (FDR <italic toggle="yes">p</italic> &#x0003c; 0.05), each exhibiting at least a three-fold difference in expression. In total, 12 of these 15 miRs were down-regulated in the high- versus low-AB groups, and the 12 miRs targeted 1673 genes. However, focusing on genes targeted by three or more of these miRs yielded only 11 genes. Furthermore, three miRs targeted four to seven different genes: miR-3202, -5481, and -3243. Thus, as few as three down-regulated miRs or as many as 15 miRs may be the strongest candidates for consideration as biomarkers for high-AB responders to an anti-drug vaccine. A parallel analysis of the exosomal miR yielded only 12 miRs at these same DE parameters, and none of these miRs overlapped between the whole blood and exosomal extractions. This lack of overlap in correlations of post-vaccination AB levels and pre-vaccination miR profiles from exosomal compared to whole blood miR was also described with Ebola virus vaccine [<xref rid="B22-vaccines-13-00181" ref-type="bibr">22</xref>]. That Ebola study identified significant correlations of specific miR with AB levels at 4 and 8 weeks after vaccination. None of those nine strongest correlations of whole blood miR with AB levels overlapped with the current study&#x02019;s 15 miRs shown in <xref rid="vaccines-13-00181-f002" ref-type="fig">Figure 2</xref>, although both studies had relatively small sample sizes of 48 currently and 30 for Ebola.</p><p>An alternative approach to finding the most important DE-miRs for distinguishing high-AB responders uses the gene targets of these DE-miRs, as applied through tissue-specific enrichment [<xref rid="B33-vaccines-13-00181" ref-type="bibr">33</xref>]. This enrichment found that gastric immune cell genes showed the strongest association of all the tissues analyzed (<italic toggle="yes">p</italic> &#x0003c; 10<sup>&#x02212;8</sup>). A similar GAD-disease class enrichment yielded a very strong association with infections (<italic toggle="yes">p</italic> &#x0003c; 0.0003) [<xref rid="B34-vaccines-13-00181" ref-type="bibr">34</xref>]. These tissue- and disease-specific associations likely reflect our use of cholera toxoid B as the cocaine hapten carrier for the anti-cocaine vaccine, leading to shared genes for AB production between this anti-cocaine vaccine and the cholera infectious disease vaccine (7). The specificity for gastric immune cell pathways may further reflect cholera&#x02019;s induction of diarrhea as its critical gut toxicity and symptom. Using a third enrichment database&#x02014;the GOTERM BP Direct enrichment&#x02014;we found that messenger RNA translation and stability had particularly strong associations with our DE miRs (<italic toggle="yes">p</italic> &#x0003c; 10<sup>&#x02212;5</sup> to &#x0003c;10<sup>&#x02212;9</sup>) [<xref rid="B33-vaccines-13-00181" ref-type="bibr">33</xref>]. Thus, the DE miRs found in our vaccine study appear to be relevant to the formation of AB against cholera, and the patients with the greater AB production also appear to have more effective pathways for specifically making miRs that inhibit messenger RNA translation.</p><p>The association of specific miRs with immunity and vaccine AB responses has implicated several miRs that regulate inflammation and cell proliferation in B cells [<xref rid="B33-vaccines-13-00181" ref-type="bibr">33</xref>,<xref rid="B34-vaccines-13-00181" ref-type="bibr">34</xref>,<xref rid="B35-vaccines-13-00181" ref-type="bibr">35</xref>,<xref rid="B36-vaccines-13-00181" ref-type="bibr">36</xref>,<xref rid="B37-vaccines-13-00181" ref-type="bibr">37</xref>,<xref rid="B38-vaccines-13-00181" ref-type="bibr">38</xref>].</p><p>Besides the Ebola vaccine, vaccination against COVID-19 has examined miRs as predictors of AB responses. The COVID vaccine study using Pfizer BNT162b2 in 61 subjects assessed only sixteen exosomal miRs in blood and identified two of interest, miR-92a-2-5p and 148a, and three others with weaker associations to AB levels: miR-132, 221, and 625-3p [<xref rid="B5-vaccines-13-00181" ref-type="bibr">5</xref>,<xref rid="B25-vaccines-13-00181" ref-type="bibr">25</xref>]. We did not identify any of these five miRs among those important for AB levels after our anti-cocaine cholera-based vaccination. However, we examined a much larger set of about 2650 miRs in both whole blood and exosomes for associations with AB levels in a similar-size sample of 48 subjects selected for high- versus low-AB responses within a sample of about 150 subjects.</p><p>Another important vaccine has been against influenza, and early vaccine studies found miR-451, miR-192, and miR-150 to be important for AB responses, and specifically elevated serum levels of miR-150 were found following MF-59-adjuvanted 2009 influenza A (H1N1) vaccination in subjects with higher AB titers [<xref rid="B39-vaccines-13-00181" ref-type="bibr">39</xref>]. Since the overexpression of miR-150 impairs the formation of mature B cells and their functional activity of making AB, reducing the expression of miR-150 could enhance the AB production following vaccination [<xref rid="B40-vaccines-13-00181" ref-type="bibr">40</xref>,<xref rid="B41-vaccines-13-00181" ref-type="bibr">41</xref>]. Interestingly, a more recent influenza study in 53 older subjects found that miR-150 was correlated with immune outcomes across several cell types, particularly in CD4+ T cells [<xref rid="B21-vaccines-13-00181" ref-type="bibr">21</xref>]. Important signaling pathways included TGF-beta, PI3K-Akt, p53, MAPK, TNF, and C-type lectin receptor signaling. We similarly found that miR-150 was the second most significant DE-miR distinguishing the high- versus low-AB responders. An additional recent study found that increased miR-150 expression in B cells was negatively correlated (<italic toggle="yes">p</italic> = 0.00038) with memory B cell ELISPOT response after influenza vaccine, likely due to mature B cell suppression or the suppression of germinal center memory B cell differentiation [<xref rid="B20-vaccines-13-00181" ref-type="bibr">20</xref>,<xref rid="B39-vaccines-13-00181" ref-type="bibr">39</xref>,<xref rid="B41-vaccines-13-00181" ref-type="bibr">41</xref>]. As further support, they found increased miR-150 expression in T cells (CD4+ and CD8+ T cells) that was negatively correlated with the AB titer. Interestingly, the intracellular miR-150 expression in T cells (e.g., CD4+ T helper cells) is down-regulated upon T cell activation to control key genes underlying T cell functions and the miR-150 is quickly released extracellularly and can be detected in blood [<xref rid="B39-vaccines-13-00181" ref-type="bibr">39</xref>,<xref rid="B42-vaccines-13-00181" ref-type="bibr">42</xref>].]. Extracellular miR-150 levels have also been a reliable serum marker of lymphocyte activation (T cell activation) [<xref rid="B43-vaccines-13-00181" ref-type="bibr">43</xref>]. Thus, miR-150 expression appears to be a reliable biomarker of influenza vaccine-induced immunity in two previous studies [<xref rid="B33-vaccines-13-00181" ref-type="bibr">33</xref>,<xref rid="B34-vaccines-13-00181" ref-type="bibr">34</xref>] as well as our current study.</p></sec><sec sec-type="conclusions" id="sec5-vaccines-13-00181"><title>5. Conclusions and Limitations</title><p>The findings of this post hoc study underscore the potential of specific miRs as biomarkers for predicting AB responses to the anti-cocaine vaccine. Our study is limited by several factors. First, its modest sample size of 48 subjects will need replication in a larger sample with a broader range of AB levels. Second, the unique focus on a haptenated vaccine that critically depends on its antigenic carrier protein cholera B toxoid for developing an antibody response is different from the infectious disease vaccines previously studied. Since our toxoid carrier showed no significant variation across subjects in its anti-cholera AB levels, our findings may not be directly relevant to infectious disease variations in AB response. Third, we focused on IgG levels, but our recent analyses suggest that IgA may be a more important component for the therapeutic effect of our vaccine for blocking cocaine abuse and may merit further examination [<xref rid="B28-vaccines-13-00181" ref-type="bibr">28</xref>]. Fourth, examining miR associated with the AB responses after the initial and three booster vaccinations may provide critical insight into how to improve this type of anti-drug vaccine efficacy. Fifth, examining all 2650 miRs reduced our statistical power compared to selecting more focused groups of miR, as had been carried out by previous studies with infectious diseases. Sixth, focusing on exosomal miR rather than whole blood miR would yield different results for our hub gene and related analyses, but using whole blood miR enabled a more detailed analysis of a larger group of miR than we found with exosomal miR. Seventh, we did not examine specific B cell functional impacts from the miR, and future studies will need to address this mediator type of an analysis. Ultimately, this study has limited generalization to other vaccines, because anti-addiction vaccines are for a special population who will also need better vaccines to address the low anti-cocaine AB levels in some participants.</p><p>Overall, replicating DE-miRs from two previous vaccine studies demonstrate the potential to identify additional replicated miRs among the other 14 significant miRs associated with high AB levels. Additionally, 3 of the 12 down-regulated DE-miRs (miR-3202, -5481, -3243) appear to jointly target four to seven genes, suggesting that these gene products may be particularly important for inhibiting AB responses to this vaccine. Overall, our three approaches to identifying the optimal miR for selecting patients most likely to benefit from these anti-addiction vaccines can be used sequentially, as we carried out. First, we found those DE-miRs that individually separate the high- from low-AB responders. Second, we selected those DE-miRs that act synergistically on genes and third, we used disease- or tissue-specific enrichments with hub genes that focus on relevant disorders like infectious disease and on processes like messenger RNA translation, which miRs specifically regulate and disrupt. Thus, the range of genes regulated by miRs can be found and provide valuable insights into the biological mechanisms underlying vaccine efficacy and become potential miR biomarkers for improving vaccination outcomes.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, T.R.K. and D.A.N.; methodology, T.R.K., A.K., C.B.D., P.H.G., C.C. and Y.T.T.; formal analysis, A.K.; investigation, T.R.K. and C.B.D.; resources, T.R.K.; data curation, C.B.D.; writing&#x02014;original draft preparation, T.R.K.; writing&#x02014;review and editing, T.R.K. and D.A.N., Y.T.T., P.H.G. and C.C.; visualization, A.K.; project administration, C.B.D.; funding acquisition, T.R.K. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board (IRB) of Baylor College of Medicine, Houston, TX (protocol H-23257). A secondary data analysis was performed within protocol H-29158, approved through the IRB of Baylor College of Medicine, Houston, TX.</p></notes><notes><title>Informed Consent Statement</title><p>Written informed consent was obtained from all subjects involved in the study.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>Data supporting reported results can be obtained through the first author, TRK, for use in appropriately approved research protocols that are consistent with the stated aims of this secondary analysis of the originally collected data from IRB protocol H-23257 funded by NIDA and conducted by TRK as PI.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.</p></notes><ref-list><title>References</title><ref id="B1-vaccines-13-00181"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kosten</surname><given-names>T.R.</given-names></name>
<name><surname>Petrakis</surname><given-names>I.L.</given-names></name>
</person-group><article-title>The Hidden Epidemic of Opioid Overdoses During the Coronavirus Disease 2019 Pandemic</article-title><source>JAMA Psychiatry</source><year>2021</year><volume>78</volume><fpage>585</fpage><lpage>586</lpage><pub-id pub-id-type="doi">10.1001/jamapsychiatry.2020.4148</pub-id><pub-id pub-id-type="pmid">33377967</pub-id>
</element-citation></ref><ref id="B2-vaccines-13-00181"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wagner</surname><given-names>K.D.</given-names></name>
<name><surname>Fiuty</surname><given-names>P.</given-names></name>
<name><surname>Page</surname><given-names>K.</given-names></name>
<name><surname>Tracy</surname><given-names>E.C.</given-names></name>
<name><surname>Nocera</surname><given-names>M.</given-names></name>
<name><surname>Miller</surname><given-names>C.W.</given-names></name>
<name><surname>Tarhuni</surname><given-names>L.J.</given-names></name>
<name><surname>Dasgupta</surname><given-names>N.</given-names></name>
</person-group><article-title>Prevalence of fentanyl in methamphetamine and cocaine samples collected by community-based drug checking services</article-title><source>Drug Alcohol Depend.</source><year>2023</year><volume>252</volume><fpage>110985</fpage><pub-id pub-id-type="doi">10.1016/j.drugalcdep.2023.110985</pub-id><pub-id pub-id-type="pmid">37826988</pub-id>
</element-citation></ref><ref id="B3-vaccines-13-00181"><label>3.</label><element-citation publication-type="gov"><person-group person-group-type="author">
<collab>Substance Abuse and Mental Health Services Administration</collab>
</person-group><article-title>Results from the 2022 National Survey on Drug Use and Health: A Companion Infographic (SAMHSA Publication No. PEP23-07-01-007). Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration</article-title><year>2023</year><comment>Available online: <ext-link xlink:href="https://www.samhsa.gov/data/report/2022-nsduh-infographic" ext-link-type="uri">https://www.samhsa.gov/data/report/2022-nsduh-infographic</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-02-02">(accessed on 2 February 2025)</date-in-citation></element-citation></ref><ref id="B4-vaccines-13-00181"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Truong</surname><given-names>T.T.</given-names></name>
<name><surname>Kosten</surname><given-names>T.R.</given-names></name>
</person-group><article-title>Current Status of Vaccines for Substance Use Disorders: A Brief Review of Human Studies</article-title><source>J. Neurol. Sci.</source><year>2021</year><volume>434</volume><fpage>120098</fpage><pub-id pub-id-type="doi">10.1016/j.jns.2021.120098</pub-id><pub-id pub-id-type="pmid">34952345</pub-id>
</element-citation></ref><ref id="B5-vaccines-13-00181"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Miyashita</surname><given-names>Y.</given-names></name>
<name><surname>Yoshida</surname><given-names>T.</given-names></name>
<name><surname>Takagi</surname><given-names>Y.</given-names></name>
<name><surname>Tsukamoto</surname><given-names>H.</given-names></name>
<name><surname>Takashima</surname><given-names>K.</given-names></name>
<name><surname>Kouwaki</surname><given-names>T.</given-names></name>
<name><surname>Makino</surname><given-names>K.</given-names></name>
<name><surname>Fukushima</surname><given-names>S.</given-names></name>
<name><surname>Nakamura</surname><given-names>K.</given-names></name>
<name><surname>Oshiumi</surname><given-names>H.</given-names></name>
</person-group><article-title>Circulating extracellular vesicle microRNAs associated with adverse reactions, proinflammatory cytokine, and antibody production after COVID-19 vaccination</article-title><source>NPJ Vaccines</source><year>2022</year><volume>7</volume><fpage>16</fpage><pub-id pub-id-type="doi">10.1038/s41541-022-00439-3</pub-id><pub-id pub-id-type="pmid">35136071</pub-id>
</element-citation></ref><ref id="B6-vaccines-13-00181"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Coffman</surname><given-names>R.L.</given-names></name>
<name><surname>Sher</surname><given-names>A.</given-names></name>
<name><surname>Seder</surname><given-names>R.A.</given-names></name>
</person-group><article-title>Vaccine Adjuvants: Putting Innate Immunity to Work</article-title><source>Immunity</source><year>2010</year><volume>33</volume><fpage>492</fpage><lpage>503</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2010.10.002</pub-id><pub-id pub-id-type="pmid">21029960</pub-id>
</element-citation></ref><ref id="B7-vaccines-13-00181"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kosten</surname><given-names>T.R.</given-names></name>
</person-group><article-title>Vaccine as Immunotherapies for Substance Use Disorders</article-title><source>Am. J. Psychiatry</source><year>2024</year><volume>181</volume><fpage>362</fpage><lpage>371</lpage><pub-id pub-id-type="doi">10.1176/appi.ajp.20230828</pub-id><pub-id pub-id-type="pmid">38706331</pub-id>
</element-citation></ref><ref id="B8-vaccines-13-00181"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kosten</surname><given-names>T.R.</given-names></name>
<name><surname>Domingo</surname><given-names>C.B.</given-names></name>
<name><surname>Haile</surname><given-names>C.N.</given-names></name>
<name><surname>Nielsen</surname><given-names>D.A.</given-names></name>
</person-group><article-title>A clinical trial of Entolimod a TLR-5 adjuvant for anti-drug vaccines using diphtheria or tetanus carrier proteins</article-title><source>Vaccines</source><year>2022</year><volume>10</volume><elocation-id>1592</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines10101592</pub-id><pub-id pub-id-type="pmid">36298456</pub-id>
</element-citation></ref><ref id="B9-vaccines-13-00181"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pinti</surname><given-names>M.</given-names></name>
<name><surname>Appay</surname><given-names>V.</given-names></name>
<name><surname>Campisi</surname><given-names>J.</given-names></name>
<name><surname>Frasca</surname><given-names>D.</given-names></name>
<name><surname>F&#x000fc;l&#x000f6;p</surname><given-names>T.</given-names></name>
<name><surname>Sauce</surname><given-names>D.</given-names></name>
<name><surname>Larbi</surname><given-names>A.</given-names></name>
<name><surname>Weinberger</surname><given-names>B.</given-names></name>
<name><surname>Cossarizza</surname><given-names>A.</given-names></name>
</person-group><article-title>Aging of the Immune System: Focus on Inflammation and Vaccination</article-title><source>Eur. J. Immunol.</source><year>2016</year><volume>46</volume><fpage>2286</fpage><lpage>2301</lpage><pub-id pub-id-type="doi">10.1002/eji.201546178</pub-id><pub-id pub-id-type="pmid">27595500</pub-id>
</element-citation></ref><ref id="B10-vaccines-13-00181"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Frasca</surname><given-names>D.</given-names></name>
<name><surname>Blomberg</surname><given-names>B.B.</given-names></name>
</person-group><article-title>Inflammaging Decreases Adaptive and Innate Immune Responses in Mice and Humans</article-title><source>Biogerontology</source><year>2016</year><volume>17</volume><fpage>7</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1007/s10522-015-9578-8</pub-id><pub-id pub-id-type="pmid">25921609</pub-id>
</element-citation></ref><ref id="B11-vaccines-13-00181"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Agarwal</surname><given-names>K.</given-names></name>
<name><surname>Manza</surname><given-names>P.</given-names></name>
<name><surname>Chapman</surname><given-names>M.</given-names></name>
<name><surname>Nawal</surname><given-names>N.</given-names></name>
<name><surname>Biesecker</surname><given-names>E.</given-names></name>
<name><surname>McPherson</surname><given-names>K.</given-names></name>
<name><surname>Dennis</surname><given-names>E.</given-names></name>
<name><surname>Johnson</surname><given-names>A.</given-names></name>
<name><surname>Volkow</surname><given-names>N.D.</given-names></name>
<name><surname>Joseph</surname><given-names>P.V.</given-names></name>
</person-group><article-title>Inflammatory Markers in Substance Use and Mood Disorders: A Neuroimaging Perspective</article-title><source>Front. Psychiatry</source><year>2022</year><volume>13</volume><elocation-id>863734</elocation-id><pub-id pub-id-type="doi">10.3389/fpsyt.2022.863734</pub-id><pub-id pub-id-type="pmid">35558424</pub-id>
</element-citation></ref><ref id="B12-vaccines-13-00181"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yang</surname><given-names>Y.</given-names></name>
<name><surname>Liu</surname><given-names>D.</given-names></name>
<name><surname>Xi</surname><given-names>Y.</given-names></name>
<name><surname>Li</surname><given-names>J.</given-names></name>
<name><surname>Liu</surname><given-names>B.</given-names></name>
<name><surname>Li</surname><given-names>J.</given-names></name>
</person-group><article-title>Upregulation of miRNA-140-5p Inhibits Inflammatory Cytokines in Acute Lung Injury Through the MyD88/NFkappaB Signaling Pathway by Targeting TLR4</article-title><source>Exp. Ther. Med.</source><year>2018</year><volume>16</volume><fpage>3913</fpage><lpage>3920</lpage><pub-id pub-id-type="doi">10.3892/etm.2018.6692</pub-id><pub-id pub-id-type="pmid">30344669</pub-id>
</element-citation></ref><ref id="B13-vaccines-13-00181"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fukushima</surname><given-names>Y.</given-names></name>
<name><surname>Okamoto</surname><given-names>M.</given-names></name>
<name><surname>Ishikawa</surname><given-names>K.</given-names></name>
<name><surname>Kouwaki</surname><given-names>T.</given-names></name>
<name><surname>Tsukamoto</surname><given-names>H.</given-names></name>
<name><surname>Oshiumi</surname><given-names>H.</given-names></name>
</person-group><article-title>Activation of TLR3 and Its Adaptor TICAM-1 Increases miR-21 Levels in Extracellular Vesicles Released From Human Cells</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2018</year><volume>500</volume><fpage>744</fpage><lpage>750</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2018.04.146</pub-id><pub-id pub-id-type="pmid">29679565</pub-id>
</element-citation></ref><ref id="B14-vaccines-13-00181"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bala</surname><given-names>S.</given-names></name>
<name><surname>Petrasek</surname><given-names>J.</given-names></name>
<name><surname>Mundkur</surname><given-names>S.</given-names></name>
<name><surname>Catalano</surname><given-names>D.</given-names></name>
<name><surname>Levin</surname><given-names>I.</given-names></name>
<name><surname>Ward</surname><given-names>J.</given-names></name>
<name><surname>Alao</surname><given-names>H.</given-names></name>
<name><surname>Kodys</surname><given-names>K.</given-names></name>
<name><surname>Szabo</surname><given-names>G.</given-names></name>
</person-group><article-title>Circulating microRNAs in Exosomes Indicate Hepatocyte Injury and Inflammation in Alcoholic, Drug-Induced, and Inflammatory Liver Diseases</article-title><source>Hepatology</source><year>2012</year><volume>56</volume><fpage>1946</fpage><lpage>1957</lpage><pub-id pub-id-type="doi">10.1002/hep.25873</pub-id><pub-id pub-id-type="pmid">22684891</pub-id>
</element-citation></ref><ref id="B15-vaccines-13-00181"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Alexander</surname><given-names>M.</given-names></name>
<name><surname>Hu</surname><given-names>R.</given-names></name>
<name><surname>Runtsch</surname><given-names>M.C.</given-names></name>
<name><surname>Kagele</surname><given-names>D.A.</given-names></name>
<name><surname>Mosbruger</surname><given-names>T.L.</given-names></name>
<name><surname>Tolmachova</surname><given-names>T.</given-names></name>
<name><surname>Seabra</surname><given-names>M.C.</given-names></name>
<name><surname>Round</surname><given-names>J.L.</given-names></name>
<name><surname>Ward</surname><given-names>D.M.</given-names></name>
<name><surname>O&#x02019;Connell</surname><given-names>R.M.</given-names></name>
</person-group><article-title>Exosome-Delivered microRNAs Modulate the Inflammatory Response to Endotoxin</article-title><source>Nat. Commun.</source><year>2015</year><volume>6</volume><fpage>7321</fpage><pub-id pub-id-type="doi">10.1038/ncomms8321</pub-id><pub-id pub-id-type="pmid">26084661</pub-id>
</element-citation></ref><ref id="B16-vaccines-13-00181"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>O&#x02019;Connell</surname><given-names>R.M.</given-names></name>
<name><surname>Rao</surname><given-names>D.S.</given-names></name>
<name><surname>Chaudhuri</surname><given-names>A.A.</given-names></name>
<name><surname>Baltimore</surname><given-names>D.</given-names></name>
</person-group><article-title>Physiological and pathological roles for microRNAs in the immune system</article-title><source>Nat. Rev. Immunol.</source><year>2010</year><volume>10</volume><fpage>111</fpage><lpage>122</lpage><pub-id pub-id-type="doi">10.1038/nri2708</pub-id><pub-id pub-id-type="pmid">20098459</pub-id>
</element-citation></ref><ref id="B17-vaccines-13-00181"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lu</surname><given-names>T.X.</given-names></name>
<name><surname>Hartner</surname><given-names>J.</given-names></name>
<name><surname>Lim</surname><given-names>E.J.</given-names></name>
<name><surname>Fabry</surname><given-names>V.</given-names></name>
<name><surname>Mingler</surname><given-names>M.K.</given-names></name>
<name><surname>Cole</surname><given-names>E.T.</given-names></name>
<name><surname>Orkin</surname><given-names>S.H.</given-names></name>
<name><surname>Aronow</surname><given-names>B.J.</given-names></name>
<name><surname>Rothenberg</surname><given-names>M.E.</given-names></name>
</person-group><article-title>MicroRNA-21 Limits In Vivo Immune Response-Mediated Activation of the IL-12/IFN-gamma Pathway, Th1 Polarization, and the Severity of Delayed-Type Hypersensitivity</article-title><source>J. Immunol.</source><year>2011</year><volume>187</volume><fpage>3362</fpage><lpage>3373</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1101235</pub-id><pub-id pub-id-type="pmid">21849676</pub-id>
</element-citation></ref><ref id="B18-vaccines-13-00181"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gao</surname><given-names>X.</given-names></name>
<name><surname>Huang</surname><given-names>X.</given-names></name>
<name><surname>Yang</surname><given-names>Q.</given-names></name>
<name><surname>Zhang</surname><given-names>S.</given-names></name>
<name><surname>Yan</surname><given-names>Z.</given-names></name>
<name><surname>Luo</surname><given-names>R.</given-names></name>
<name><surname>Wang</surname><given-names>P.</given-names></name>
<name><surname>Wang</surname><given-names>W.</given-names></name>
<name><surname>Xie</surname><given-names>K.</given-names></name>
<name><surname>Gun</surname><given-names>S.</given-names></name>
</person-group><article-title>MicroRNA-21-5p Targets PDCD4 to Modulate Apoptosis and Inflammatory Response to Clostridium Perfringens Beta2 Toxin Infection in IPEC-J2 Cells</article-title><source>Dev. Comp. Immunol.</source><year>2021</year><volume>114</volume><fpage>103849</fpage><pub-id pub-id-type="doi">10.1016/j.dci.2020.103849</pub-id><pub-id pub-id-type="pmid">32888967</pub-id>
</element-citation></ref><ref id="B19-vaccines-13-00181"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dai</surname><given-names>R.</given-names></name>
<name><surname>Ahmed</surname><given-names>S.A.</given-names></name>
</person-group><article-title>MicroRNA, a new paradigm for understanding immunoregulation, inflammation, and autoimmune diseases</article-title><source>Transl. Res.</source><year>2011</year><volume>157</volume><fpage>163</fpage><lpage>179</lpage><pub-id pub-id-type="doi">10.1016/j.trsl.2011.01.007</pub-id><!--<pub-id pub-id-type="pmcid">PMC3072681</pub-id>--><pub-id pub-id-type="pmid">21420027</pub-id>
</element-citation></ref><ref id="B20-vaccines-13-00181"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>J.</given-names></name>
<name><surname>Chen</surname><given-names>J.</given-names></name>
<name><surname>Sen</surname><given-names>S.</given-names></name>
</person-group><article-title>MicroRNA as Biomarkers and Diagnostics</article-title><source>J. Cell Physiol.</source><year>2016</year><volume>231</volume><fpage>25</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1002/jcp.25056</pub-id><pub-id pub-id-type="pmid">26031493</pub-id>
</element-citation></ref><ref id="B21-vaccines-13-00181"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Haralambieva</surname><given-names>I.H.</given-names></name>
<name><surname>Ratishvili</surname><given-names>T.</given-names></name>
<name><surname>Goergen</surname><given-names>K.M.</given-names></name>
<name><surname>Grill</surname><given-names>D.E.</given-names></name>
<name><surname>Simon</surname><given-names>W.L.</given-names></name>
<name><surname>Chen</surname><given-names>J.</given-names></name>
<name><surname>Ovsyannikova</surname><given-names>I.G.</given-names></name>
<name><surname>Poland</surname><given-names>G.A.</given-names></name>
<name><surname>Kennedy</surname><given-names>R.B.</given-names></name>
</person-group><article-title>Effect of Lymphocyte miRNA Expression on Influenza Vaccine-Induced Immunity</article-title><source>medRxiv</source><year>2024</year><pub-id pub-id-type="doi">10.1101/2024.11.02.24316654</pub-id></element-citation></ref><ref id="B22-vaccines-13-00181"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vianello</surname><given-names>E.</given-names></name>
<name><surname>Persson</surname><given-names>J.</given-names></name>
<name><surname>Andersson</surname><given-names>B.</given-names></name>
<name><surname>van Veen</surname><given-names>S.</given-names></name>
<name><surname>Dias</surname><given-names>T.L.</given-names></name>
<name><surname>Santoro</surname><given-names>F.</given-names></name>
<name><surname>&#x000d6;stensson</surname><given-names>M.</given-names></name>
<name><surname>Obudulu</surname><given-names>O.</given-names></name>
<name><surname>Agbajogu</surname><given-names>C.</given-names></name>
<name><surname>Torkzadeh</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Global blood miRNA profiling unravels early signatures of immunogenicity of Ebola vaccine rVSV&#x00394;G-ZEBOV-GP</article-title><source>iScience</source><year>2023</year><volume>26</volume><fpage>108574</fpage><pub-id pub-id-type="doi">10.1016/j.isci.2023.108574</pub-id><pub-id pub-id-type="pmid">38162033</pub-id>
</element-citation></ref><ref id="B23-vaccines-13-00181"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Xu</surname><given-names>N.</given-names></name>
<name><surname>Zhao</surname><given-names>S.</given-names></name>
<name><surname>Jiao</surname><given-names>T.</given-names></name>
<name><surname>Fu</surname><given-names>W.</given-names></name>
<name><surname>Yang</surname><given-names>L.</given-names></name>
<name><surname>Zhang</surname><given-names>N.</given-names></name>
</person-group><article-title>Mir-410-3p suppresses cytokine release from fibroblast-like synoviocytes by regulating NF-kappaB signaling in rheumatoid arthritis</article-title><source>Inflammation</source><year>2019</year><volume>42</volume><fpage>331</fpage><lpage>341</lpage><pub-id pub-id-type="doi">10.1007/s10753-018-0896-2</pub-id><pub-id pub-id-type="pmid">30242542</pub-id>
</element-citation></ref><ref id="B24-vaccines-13-00181"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>S.</given-names></name>
<name><surname>Geng</surname><given-names>Q.</given-names></name>
<name><surname>Zhang</surname><given-names>H.</given-names></name>
<name><surname>Du</surname><given-names>Q.</given-names></name>
<name><surname>Wei</surname><given-names>Q.</given-names></name>
<name><surname>Cui</surname><given-names>Y.</given-names></name>
<name><surname>Zhang</surname><given-names>X.</given-names></name>
<name><surname>Yuan</surname><given-names>M.</given-names></name>
</person-group><article-title>Downregulation of miR-98-5p expression induces interleukin-6 expression in rheumatoid fibroblast-like synoviocytes</article-title><source>Int. J. Rheum. Dis.</source><year>2021</year><volume>24</volume><fpage>1024</fpage><lpage>1031</lpage><pub-id pub-id-type="doi">10.1111/1756-185X.14160</pub-id><pub-id pub-id-type="pmid">34155816</pub-id>
</element-citation></ref><ref id="B25-vaccines-13-00181"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tsukamoto</surname><given-names>H.</given-names></name>
<name><surname>Kouwaki</surname><given-names>T.</given-names></name>
<name><surname>Oshiumi</surname><given-names>H.</given-names></name>
</person-group><article-title>Aging-associated extracellular vesicles contain immune regulatory microRNAs alleviating hyperinflammatory state and immune dysfunction in the elderly</article-title><source>iScience</source><year>2020</year><volume>23</volume><fpage>101520</fpage><pub-id pub-id-type="doi">10.1016/j.isci.2020.101520</pub-id><pub-id pub-id-type="pmid">32927264</pub-id>
</element-citation></ref><ref id="B26-vaccines-13-00181"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kosten</surname><given-names>T.R.</given-names></name>
<name><surname>Domingo</surname><given-names>C.B.</given-names></name>
<name><surname>Shorter</surname><given-names>D.</given-names></name>
<name><surname>Orson</surname><given-names>F.</given-names></name>
<name><surname>Green</surname><given-names>C.</given-names></name>
<name><surname>Somoza</surname><given-names>E.</given-names></name>
<name><surname>Sekerka</surname><given-names>R.</given-names></name>
<name><surname>Levin</surname><given-names>F.R.</given-names></name>
<name><surname>Mariani</surname><given-names>J.J.</given-names></name>
<name><surname>Stitzer</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Vaccine for cocaine dependence: A randomized double-blind placebo-controlled efficacy trial</article-title><source>Drug Alcohol Depend.</source><year>2014</year><volume>140</volume><fpage>42</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1016/j.drugalcdep.2014.04.003</pub-id><!--<pub-id pub-id-type="pmcid">PMC4073297</pub-id>--><pub-id pub-id-type="pmid">24793366</pub-id>
</element-citation></ref><ref id="B27-vaccines-13-00181"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Orson</surname><given-names>F.M.</given-names></name>
<name><surname>Rossen</surname><given-names>R.D.</given-names></name>
<name><surname>Shen</surname><given-names>X.</given-names></name>
<name><surname>Lopez</surname><given-names>A.Y.</given-names></name>
<name><surname>Wu</surname><given-names>Y.</given-names></name>
<name><surname>Kosten</surname><given-names>T.R.</given-names></name>
</person-group><article-title>Spontaneous development of IgM anti-cocaine antibodies in habitual cocaine users: Effect on IgG antibody responses to a cocaine cholera toxin B conjugate vaccine</article-title><source>Am. J. Addict.</source><year>2013</year><volume>22</volume><fpage>169</fpage><lpage>174</lpage><pub-id pub-id-type="doi">10.1111/j.1521-0391.2013.00314.x</pub-id><!--<pub-id pub-id-type="pmcid">PMC4143984</pub-id>--><pub-id pub-id-type="pmid">23414504</pub-id>
</element-citation></ref><ref id="B28-vaccines-13-00181"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kosten</surname><given-names>T.R.</given-names></name>
<name><surname>Domingo</surname><given-names>C.B.</given-names></name>
<name><surname>Haile</surname><given-names>C.N.</given-names></name>
<name><surname>Norton</surname><given-names>E.B.</given-names></name>
</person-group><article-title>Anti-cocaine IgA rather than IgG mediates vaccine protection from cocaine use</article-title><source>Pharmaceutics</source><year>2022</year><volume>14</volume><elocation-id>2368</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics14112368</pub-id><!--<pub-id pub-id-type="pmcid">PMC9697488</pub-id>--><pub-id pub-id-type="pmid">36365186</pub-id>
</element-citation></ref><ref id="B29-vaccines-13-00181"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dobin</surname><given-names>A.</given-names></name>
<name><surname>Davis</surname><given-names>C.A.</given-names></name>
<name><surname>Schlesinger</surname><given-names>F.</given-names></name>
<name><surname>Drenkow</surname><given-names>J.</given-names></name>
<name><surname>Zaleski</surname><given-names>C.</given-names></name>
<name><surname>Jha</surname><given-names>S.</given-names></name>
<name><surname>Batut</surname><given-names>P.</given-names></name>
<name><surname>Chaisson</surname><given-names>M.</given-names></name>
<name><surname>Gingeras</surname><given-names>T.R.</given-names></name>
</person-group><article-title>STAR: Ultrafast universal RNA-seq aligner</article-title><source>Bioinformatics</source><year>2013</year><volume>29</volume><fpage>15</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bts635</pub-id><pub-id pub-id-type="pmid">23104886</pub-id>
</element-citation></ref><ref id="B30-vaccines-13-00181"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kozomara</surname><given-names>A.</given-names></name>
<name><surname>Birgaoanu</surname><given-names>M.</given-names></name>
<name><surname>Griffiths-Jones</surname><given-names>S.</given-names></name>
</person-group><article-title>miRBase: From microRNA sequences to function</article-title><source>Nucleic Acids Res.</source><year>2019</year><volume>47</volume><fpage>D155</fpage><lpage>D162</lpage><pub-id pub-id-type="doi">10.1093/nar/gky1141</pub-id><!--<pub-id pub-id-type="pmcid">PMC6323917</pub-id>--><pub-id pub-id-type="pmid">30423142</pub-id>
</element-citation></ref><ref id="B31-vaccines-13-00181"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Matias-Garcia</surname><given-names>P.R.</given-names></name>
<name><surname>Wilson</surname><given-names>R.</given-names></name>
<name><surname>Mussack</surname><given-names>V.</given-names></name>
<name><surname>Reischl</surname><given-names>E.</given-names></name>
<name><surname>Waldenberger</surname><given-names>M.</given-names></name>
<name><surname>Gieger</surname><given-names>C.</given-names></name>
<name><surname>Anton</surname><given-names>G.</given-names></name>
<name><surname>Peters</surname><given-names>A.</given-names></name>
<name><surname>Kuehn-Steven</surname><given-names>A.</given-names></name>
</person-group><article-title>Impact of long-term storage and freeze-thawing on eight circulating microRNAs in plasma samples</article-title><source>PLoS ONE</source><year>2020</year><volume>15</volume><elocation-id>e0227648</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0227648</pub-id><pub-id pub-id-type="pmid">31935258</pub-id>
</element-citation></ref><ref id="B32-vaccines-13-00181"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
</person-group><article-title>miRDB: An online database for prediction of functional microRNA targets</article-title><source>Nucleic Acids Res.</source><year>2020</year><volume>48</volume><fpage>D127</fpage><lpage>D131</lpage><pub-id pub-id-type="doi">10.1093/nar/gkz757</pub-id><!--<pub-id pub-id-type="pmcid">PMC6943051</pub-id>--><pub-id pub-id-type="pmid">31504780</pub-id>
</element-citation></ref><ref id="B33-vaccines-13-00181"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ashburner</surname><given-names>M.</given-names></name>
<name><surname>Ball</surname><given-names>C.A.</given-names></name>
<name><surname>Blake</surname><given-names>J.A.</given-names></name>
<name><surname>Botstein</surname><given-names>D.</given-names></name>
<name><surname>Butler</surname><given-names>H.</given-names></name>
<name><surname>Cherry</surname><given-names>J.M.</given-names></name>
<name><surname>Davis</surname><given-names>A.P.</given-names></name>
<name><surname>Dolinski</surname><given-names>K.</given-names></name>
<name><surname>Dwight</surname><given-names>S.S.</given-names></name>
<name><surname>Eppig</surname><given-names>J.T.</given-names></name>
<etal/>
</person-group><article-title>Gene ontology: Tool for the unification of biology</article-title><source>Nat. Genet.</source><year>2000</year><volume>25</volume><fpage>25</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1038/75556</pub-id><pub-id pub-id-type="pmid">10802651</pub-id>
</element-citation></ref><ref id="B34-vaccines-13-00181"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Silberstein</surname><given-names>M.</given-names></name>
<name><surname>Nesbit</surname><given-names>N.</given-names></name>
<name><surname>Cai</surname><given-names>J.</given-names></name>
<name><surname>Lee</surname><given-names>P.H.</given-names></name>
</person-group><article-title>Pathway analysis for genome-wide genetic variation data: Analytic principles, latest developments, and new opportunities</article-title><source>J. Genet. Genom.</source><year>2021</year><volume>48</volume><fpage>173</fpage><lpage>183</lpage><pub-id pub-id-type="doi">10.1016/j.jgg.2021.01.007</pub-id><!--<pub-id pub-id-type="pmcid">PMC8286309</pub-id>--><pub-id pub-id-type="pmid">33896739</pub-id>
</element-citation></ref><ref id="B35-vaccines-13-00181"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>J.</given-names></name>
<name><surname>Wan</surname><given-names>Y.</given-names></name>
<name><surname>Ji</surname><given-names>Q.</given-names></name>
<name><surname>Fang</surname><given-names>Y.</given-names></name>
<name><surname>Wu</surname><given-names>Y.</given-names></name>
</person-group><article-title>The role of microRNAs in B-cell development and function</article-title><source>Cell. Mol. Immunol.</source><year>2013</year><volume>10</volume><fpage>107</fpage><lpage>112</lpage><pub-id pub-id-type="doi">10.1038/cmi.2012.62</pub-id><pub-id pub-id-type="pmid">23314697</pub-id>
</element-citation></ref><ref id="B36-vaccines-13-00181"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Li</surname><given-names>Y.K.</given-names></name>
</person-group><article-title>MicroRNAs in the regulation of immune response against infections</article-title><source>J. Zhejiang Univ. Sci. B.</source><year>2013</year><volume>14</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1631/jzus.B1200292</pub-id><pub-id pub-id-type="pmid">23303626</pub-id>
</element-citation></ref><ref id="B37-vaccines-13-00181"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chandan</surname><given-names>K.</given-names></name>
<name><surname>Gupta</surname><given-names>M.</given-names></name>
<name><surname>Sarwat</surname><given-names>M.</given-names></name>
</person-group><article-title>Role of Host and Pathogen-Derived MicroRNAs in Immune Regulation During Infectious and Inflammatory Diseases</article-title><source>Front. Immunol.</source><year>2020</year><volume>10</volume><elocation-id>3081</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2019.03081</pub-id><pub-id pub-id-type="pmid">32038627</pub-id>
</element-citation></ref><ref id="B38-vaccines-13-00181"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Girardi</surname><given-names>C.</given-names></name>
<name><surname>De Pitt&#x000e0;</surname><given-names>C.</given-names></name>
<name><surname>Casara</surname><given-names>S.</given-names></name>
<name><surname>Calura</surname><given-names>E.</given-names></name>
<name><surname>Romualdi</surname><given-names>C.</given-names></name>
<name><surname>Celotti</surname><given-names>L.</given-names></name>
<name><surname>Mognato</surname><given-names>M.</given-names></name>
</person-group><article-title>Integration analysis of microRNA and mRNA expression profiles in human peripheral blood lymphocytes cultured in modeled microgravity</article-title><source>BioMed Res. Int.</source><year>2014</year><volume>2014</volume><elocation-id>296747</elocation-id><pub-id pub-id-type="doi">10.1155/2014/296747</pub-id><pub-id pub-id-type="pmid">25045661</pub-id>
</element-citation></ref><ref id="B39-vaccines-13-00181"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>de Candia</surname><given-names>P.</given-names></name>
<name><surname>Torri</surname><given-names>A.</given-names></name>
<name><surname>Gorletta</surname><given-names>T.</given-names></name>
<name><surname>Fedeli</surname><given-names>M.</given-names></name>
<name><surname>Bulgheroni</surname><given-names>E.</given-names></name>
<name><surname>Cheroni</surname><given-names>C.</given-names></name>
<name><surname>Marabita</surname><given-names>F.</given-names></name>
<name><surname>Crosti</surname><given-names>M.</given-names></name>
<name><surname>Moro</surname><given-names>M.</given-names></name>
<name><surname>Pariani</surname><given-names>E.</given-names></name>
<etal/>
</person-group><article-title>Intracellular modulation, extracellular disposal and serum increase of MiR-150 mark lymphocyte activation</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><elocation-id>e75348</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0075348</pub-id><pub-id pub-id-type="pmid">24205408</pub-id>
</element-citation></ref><ref id="B40-vaccines-13-00181"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhou</surname><given-names>B.</given-names></name>
<name><surname>Wang</surname><given-names>S.</given-names></name>
<name><surname>Mayr</surname><given-names>C.</given-names></name>
<name><surname>Bartel</surname><given-names>D.P.</given-names></name>
<name><surname>Lodish</surname><given-names>H.F.</given-names></name>
</person-group><article-title>miR-150, a microRNA expressed in mature B and T cells, blocks early B cell development when expressed prematurely</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2007</year><volume>104</volume><fpage>7080</fpage><lpage>7085</lpage><pub-id pub-id-type="doi">10.1073/pnas.0702409104</pub-id><pub-id pub-id-type="pmid">17438277</pub-id>
</element-citation></ref><ref id="B41-vaccines-13-00181"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Inoue</surname><given-names>T.</given-names></name>
<name><surname>Memory</surname><given-names>B.</given-names></name>
</person-group><article-title>cell differentiation from germinal centers</article-title><source>Int. Immunol.</source><year>2023</year><volume>35</volume><fpage>565</fpage><lpage>570</lpage><pub-id pub-id-type="doi">10.1093/intimm/dxad017</pub-id><pub-id pub-id-type="pmid">37232558</pub-id>
</element-citation></ref><ref id="B42-vaccines-13-00181"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pagani</surname><given-names>M.</given-names></name>
<name><surname>Rossetti</surname><given-names>G.</given-names></name>
<name><surname>Panzeri</surname><given-names>I.</given-names></name>
<name><surname>de Candia</surname><given-names>P.</given-names></name>
<name><surname>Bonnal</surname><given-names>R.J.</given-names></name>
<name><surname>Rossi</surname><given-names>R.L.</given-names></name>
<name><surname>Geginat</surname><given-names>J.</given-names></name>
<name><surname>Abrignani</surname><given-names>S.</given-names></name>
</person-group><article-title>Role of microRNAs and long-non-coding RNAs in CD4(+) T-cell differentiation</article-title><source>Immunol. Rev.</source><year>2013</year><volume>253</volume><fpage>82</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1111/imr.12055</pub-id><pub-id pub-id-type="pmid">23550640</pub-id>
</element-citation></ref><ref id="B43-vaccines-13-00181"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>de Candia</surname><given-names>P.</given-names></name>
<name><surname>Torri</surname><given-names>A.</given-names></name>
<name><surname>Pagani</surname><given-names>M.</given-names></name>
<name><surname>Abrignani</surname><given-names>S.</given-names></name>
</person-group><article-title>Serum microRNAs as Biomarkers of Human Lymphocyte Activation in Health and Disease</article-title><source>Front Immunol.</source><year>2014</year><volume>5</volume><fpage>43</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2014.00043</pub-id><pub-id pub-id-type="pmid">24575093</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="vaccines-13-00181-f001"><label>Figure 1</label><caption><p>Plot of mean DE-miR for subjects with high vs. low cocaine AB levels. (Significantly different miRs (FDR <italic toggle="yes">p</italic> &#x0003c; 0.05 and fold change (FC) &#x0003e; 3-fold) between subjects having high versus low peak AB levels are labeled and in two colors&#x02014;blue or red. Blue dots are significantly down-regulated miRs and red dots are significantly up-regulated miRs; gray dots are miRs that show no significant difference).</p></caption><graphic xlink:href="vaccines-13-00181-g001" position="float"/></fig><fig position="float" id="vaccines-13-00181-f002"><label>Figure 2</label><caption><p>Heatmap of individual subject&#x02019;s AB level Z-scores for every microRNA that significantly distinguished subjects in high- versus low-AB groups.</p></caption><graphic xlink:href="vaccines-13-00181-g002" position="float"/></fig><fig position="float" id="vaccines-13-00181-f003"><label>Figure 3</label><caption><p>Genes targeted by three or more of eleven significantly down-regulated miRs (blue circles are genes, and orange diamonds are miRs with lines showing genes regulated by a particular miR).</p></caption><graphic xlink:href="vaccines-13-00181-g003" position="float"/></fig></floats-group></article>